2017 Susie Novis Durie Grant accepting applications

In 2016, the Global Myeloma Action Network (GMAN) launched the Susie Novis Durie Grant program in honor of IMF President and Founder. For 27 years, Susie’s tireless efforts to develop and implement innovative patient programs in the area of myeloma have helped countless patients around the globe. Susie has been instrumental in changing the landscape of myeloma, and many of the programs that she initiated have become models for other organizations worldwide. The Susie Novis Durie Grant provides funding to GMAN coalition members to support projects that advance the GMAN mission and expand upon Susie’s vision to improve the lives of myeloma patients around the world by raising the profile and enhancing the capabilities of patient advocacy groups, increasing myeloma awareness, and improving patients access to myeloma treatments. In 2017, three merit-based Grants in the amount of $5,000 each will be awarded to member organizations. To apply by the deadline of May 19, please click HERE.

Transplantation for myeloma patients: Can it wait?

For people with myeloma who have access to new therapies, a big question remains. Can a stem cell transplant wait? The Intergroupe Francophone du Mylome (IFM) 2009 trial, published online April 6 in the New England Journal of Medicine addresses this question among others. Results show that after induction with lenalidomide + bortezomib + dexamethasone, survival for patients who received transplants as part of consolidation therapy was similar to that for patients who received transplants following relapse. However, progression-free survival and response rates were higher for patients in the early transplant group. “This benefit must be weighed against the increased risk of toxic effects associated with high-dose chemotherapy plus transplantation, especially since we found that later transplantation might be as effective as early transplantation in securing long-term survival,” the investigators concluded. Myeloma expert Dr. S. Vincent Rajkumar (Mayo Clinic, Rochester, Minnesota), who was not associated with the study, explained in a related commentary that as long as transplant is performed, the timing of early vs. late transplant can be made on the basis of patient preferences. “This trial shows we can abide by patients’ wishes and circumstances, with a few exceptions,” he said.

PET/CT scanning comes of age: New IMWG Guidelines

New IMWG guidelines for PET/CT scanning have been published in The Lancet Oncology medical journal. IMF Chairman Dr. Brian G.M. Durie congratulates Dr. Michele Cavo and his team of investigators for their report on this extremely accurate imaging technique, used to establish a diagnosis and to monitor myeloma patients throughout the course of their disease. The new IMWG guidelines provide a comprehensive review of the current role and optimal uses of FDG PET/ CT scanning, he writes. To read Dr. Durie’s blog, click HERE.


Two 2017 updated publications available from the IMF

The 2017 editions of the IMF’s Patient Handbook and Concise Review of the Disease and Treatment Options can be read or downloaded HERE. These educational publications are currently available only in English; translations into several languages are pending.

We Thank Our Sponsors: Amgen, Bristol-Myers Squibb, Celgene, Genentech, and Takeda.

Events in Madrid International Patient Seminars

June 17-19
GMAN Annual Summit

June 17-19
IMWG Annual Summit

June 22-25
EHA Annual Summit

May 6
IMF Patient & Family Seminar La Hulpe, Belgium

June 10
IMF Patient & Family Seminar Paris, France